Nanobiotix S.A.
EPA:NANO.PA
4.454 (EUR) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) EUR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 30.058 | 4.776 | 0.01 | 0.05 | 0.068 | 3.479 | 3.722 | 5.422 | 4.015 | 2.771 | 0.185 | 0.074 | 1.36 |
| Cost of Revenue
| -6.15 | 1.5 | -2.637 | -2.275 | -2.473 | 0 | 0.346 | 0.436 | 0.36 | 0 | 0 | 0 | 0 |
| Gross Profit
| 36.208 | 3.276 | 2.647 | 2.325 | 2.541 | 3.479 | 3.376 | 4.985 | 3.656 | 2.771 | 0.185 | 0.074 | 1.36 |
| Gross Profit Ratio
| 1.205 | 0.686 | 264.7 | 46.5 | 37.368 | 1 | 0.907 | 0.92 | 0.91 | 1 | 1 | 1 | 1 |
| Reseach & Development Expenses
| 37.101 | 31.471 | 29.234 | 22.928 | 28.802 | 20.893 | 17.733 | 16.915 | 13.902 | 8.076 | 6.026 | 4.312 | 5.213 |
| General & Administrative Expenses
| 21.661 | 0 | 19.017 | 14.271 | 18.64 | 12.619 | 12.335 | 10.257 | 7.188 | 4.063 | 3.611 | 1.807 | 1.3 |
| Selling & Marketing Expenses
| 0.002 | 0 | 0.001 | -0.052 | -0.004 | 0.034 | -1.08 | 0.104 | 0.067 | 0.252 | 0 | 0 | 0 |
| SG&A
| 21.663 | 17.479 | 19.018 | 14.219 | 18.636 | 12.653 | 11.255 | 10.361 | 7.255 | 4.315 | 3.611 | 1.807 | 1.3 |
| Other Expenses
| -0.163 | -0.043 | 0 | -0.04 | -0.052 | 0 | -0.338 | 0.16 | 0 | 0 | 2.339 | 0.915 | 0.015 |
| Operating Expenses
| 58.927 | 48.993 | 48.252 | 37.187 | 47.49 | 33.011 | 29.79 | 27.169 | 21.142 | 12.389 | 8.364 | 5.227 | 5.227 |
| Operating Income
| -30.387 | -50.493 | -49.802 | -38.892 | -49.192 | -30.067 | -25.266 | -21.855 | -17.142 | -9.62 | -8.179 | -5.153 | -5.227 |
| Operating Income Ratio
| -1.011 | -10.572 | -4,980.2 | -777.84 | -723.412 | -8.642 | -6.788 | -4.031 | -4.269 | -3.472 | -44.228 | -69.489 | -3.843 |
| Total Other Income Expenses Net
| -13.132 | -10.629 | 0.313 | 3.384 | -4.157 | -0.278 | -0.877 | 0.065 | 0.139 | 0.143 | -0.002 | -0.022 | -0 |
| Income Before Tax
| -43.519 | -61.122 | -49.489 | -35.508 | -53.349 | -30.345 | -26.143 | -21.79 | -17.003 | -9.477 | -8.145 | -5.252 | -5.247 |
| Income Before Tax Ratio
| -1.448 | -12.798 | -4,948.9 | -710.16 | -784.544 | -8.722 | -7.024 | -4.019 | -4.235 | -3.42 | -44.041 | -70.827 | -3.857 |
| Income Tax Expense
| -3.819 | -4.081 | -2.486 | -1.918 | -2.434 | -3.251 | -3.259 | 0.09 | -3.546 | 0.079 | -0.034 | 0.079 | 0.019 |
| Net Income
| -39.7 | -57.041 | -47.003 | -33.59 | -50.915 | -30.345 | -26.143 | -21.881 | -17.003 | -9.557 | -8.145 | -5.331 | -5.247 |
| Net Income Ratio
| -1.321 | -11.943 | -4,700.3 | -671.8 | -748.75 | -8.722 | -7.024 | -4.036 | -4.235 | -3.449 | -44.041 | -71.89 | -3.857 |
| EPS
| -1.08 | -1.64 | -1.35 | -1.38 | -2.35 | -1.55 | -1.5 | -1.43 | -1.2 | -0.74 | -0.76 | -0.65 | -3.42 |
| EPS Diluted
| -1.08 | -1.64 | -1.35 | -1.38 | -2.35 | -1.55 | -1.5 | -1.43 | -1.2 | -0.74 | -0.76 | -0.65 | -3.42 |
| EBITDA
| -28.869 | -48.993 | -48.242 | -37.137 | -47.422 | -29.448 | -24.812 | -21.372 | -16.686 | -9.312 | -7.886 | -5.028 | -5.018 |
| EBITDA Ratio
| -0.96 | -10.258 | -4,824.2 | -742.74 | -697.382 | -8.465 | -6.666 | -3.942 | -4.156 | -3.361 | -42.644 | -67.812 | -3.689 |